Frequency Therapeutics (FREQ)
In a report issued on January 8, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Frequency Therapeutics, with a price target of $79.00. The company’s shares closed last Thursday at $36.76.
According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 34.3% and a 59.1% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals.
Frequency Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $63.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.